The ‘LUNGFUL’ study provides real-world evidence from routine care clinical settings in Greece on the frequency of EGFR mutations, focusing on T790M, in patients with EGFR-mutated advanced NSCLC who have progressed in the first-line EGFR-TKI (1st or 2nd generation) treatment setting. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.